» Articles » PMID: 16627550

Expression of Chemokine Receptors Predicts the Site of Metastatic Relapse in Patients with Axillary Node Positive Primary Breast Cancer

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2006 Apr 22
PMID 16627550
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies have suggested that chemokine receptors are involved in development of organ-specific pattern of metastases. In the present study, we evaluated the association between the chemokine receptors expressed in primary tumor cells and the site of metastatic relapse in patients with breast cancer.

Methods: Primary tumors were obtained from 142 patients with axillary node-positive breast cancer and stained for CX3CR1, CXCR4, CCR6, and CCR7 expression. All statistical analyses were adjusted for systemic post-operative treatment.

Results: After a median follow-up of 13 years, none of the chemokine receptors was associated with overall survival or disease free survival. However, expression of chemokine receptors was found to be associated with increased risk of relapse in certain organs. By estimating the Mantel-Haenszel odds ratios (OR), CXCR4 was associated with increased risk of metastasis to the liver (OR = 3.71, P = 0.005), CX3CR1 was associated with metastasis to the brain (OR = 13.18, P = 0.01). Patients with CCR6 positivity were more likely to develop a first metastasis in the pleura (OR = 2.82, P = 0.06). In addition, CCR7 expression was associated with the occurrence of skin metastases (11% versus 0%, P = 0.017).

Interpretation: Expression of chemokine receptors in the primary tumor predicts the site of metastatic relapse in patients with axillary node positive breast cancer. This study, in concordance with the data obtained in animal models, suggests that the chemokine receptors family could be the biological support of the 'seed and soil' theory.

Citing Articles

Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis.

Nakagawa R, Izumi K, Hiratsuka K, Inaba T, Koketsu Y, Toriumi R Neoplasia. 2024; 60:101103.

PMID: 39700633 PMC: 11729035. DOI: 10.1016/j.neo.2024.101103.


Association of Sympathovagal Imbalance with Increased Inflammation and Impaired Adaptive Immunity in Bladder Cancer Patients.

Mikolaskova I, Zvarik M, Szaboova K, Tibenska E, Durmanova V, Suchankova M Int J Mol Sci. 2024; 25(23).

PMID: 39684475 PMC: 11641687. DOI: 10.3390/ijms252312765.


New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer.

Cabioglu N, Onder S, Karatay H, Bayram A, Oner G, Tukenmez M Cancers (Basel). 2024; 16(13).

PMID: 39001456 PMC: 11240792. DOI: 10.3390/cancers16132388.


Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.

Bagbudar S, Karanlik H, Cabioglu N, Bayram A, Tukenmez M, Aydiner A Med Oncol. 2023; 41(1):18.

PMID: 38102446 DOI: 10.1007/s12032-023-02243-y.


Exploring the role of miR-200 family in regulating CX3CR1 and CXCR1 in lung adenocarcinoma tumor microenvironment: implications for therapeutic intervention.

Sharma A, Singh P, Jha R, Almatroodi S, Alrumaihi F, Rahmani A Sci Rep. 2023; 13(1):16333.

PMID: 37770496 PMC: 10539366. DOI: 10.1038/s41598-023-43484-1.